The acquisition of Adheron Therapeutics by Roche (announced last Friday) for its SDP051 programme, a therapeutic antibody created using Abzena’s Composite Human AntibodyTM platform, provides further validation of Abzena’s technology offering. A total of 10 Composite Human AntibodiesTM are currently in clinical trials with partners (including Gilead Sciences and now Roche). The high acquisition price (up to $580m) for Adheron, a single-asset company, also supports a significant sales potential of ....
